Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant pharmacokinetics in hepatic impairment
NCT05440344Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imlunestrant (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration of Imlunestrant at Day 1 and Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration of Imlunestrant at Day 1. Started Jul 2022; status: completed.
02
Drugs
imlunestrant
Beyond the preview
Go deeper on NCT05440344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440344.